Cimzia® - Psoriatic arthritis (PsA)

Europe

In Europe, Cimzia®, in combination with MTX, is indicated for the treatment of active psoriatic arthritis in adults when the response to previous DMARD therapy has been inadequate.
Cimzia® can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate.

USA

In the US, Cimzia® (certolizumab pegol) is a tumor necrosis factor (TNF) blocker indicated for the treatment of adult patients with active psoriatic arthritis (PsA).

Warning: serious infections and malignancy

See full prescribing information for complete boxed warning.

• Increased risk of serious infections leading to hospitalisation or death including tuberculosis (TB), bacterial sepsis, invasive fungal infections (such as histoplasmosis), and infections due to other opportunistic pathogens (5.1)
• Cimzia should be discontinued if a patient develops a serious infection or sepsis (5.1)
• Perform test for latent TB; if positive, start treatment for TB prior to starting Cimzia (5.1)
• Monitor all patients for active TB during treatment, even if initial latent TB test is negative (5.1)
• Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers, of which Cimzia is a member (5.2). Cimzia is not indicated for use in pediatric patients (8.4).

Prescribing information Europe

• SmPC Cimzia® (EU). Sourced from www.ema.europe.eu

Related website

• Cimzia® product website (for US residents only)